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ttp://dx.doi.org/10.1016/j.jmoldx.2013.03.008Myotonic dystrophy type 1 (DM1) is caused by expansion of a CTG triplet repeat in the 30 untranslated region
of the DMPK gene that encodes a serine-threonine kinase. Patients with larger repeats tend to have a more
severe phenotype. Clinical laboratories require reference and quality control materials for DM1 diagnostic
and carrier genetic testing. Well-characterized reference materials are not available. To address this need,
the Centers for Disease Control and Preventionebased Genetic Testing Reference Material Coordination
Program, in collaboration with members of the genetic testing community, the National Registry of
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members, and the
Coriell Cell Repositories, has established and characterized cell lines from patients with DM1 to create
a reference material panel. The CTG repeats in genomic DNA samples from 10 DM1 cell lines were charac-
terized in three clinical genetic testing laboratories using PCR and Southern blot analysis. DMPK alleles in
the samples cover four of ﬁve DM1 clinical categories: normal (5 to 34 repeats), mild (50 to 100 repeats),
classical (101 to 1000 repeats), and congenital (>1000 repeats). We did not identify or establish Coriell cell
lines in the premutation range (35 to 49 repeats). These samples are publicly available for quality control,
proﬁciency testing, test development, and research and should help improve the accuracy of DM1 testing.
(J Mol Diagn 2013, 15: 518e525; http://dx.doi.org/10.1016/j.jmoldx.2013.03.008)The National Registry is supported through the National Institute of
Arthritis and Musculoskeletal and Skin Diseases and the National Institute
of Neurological Disorders and Stroke (NIH Senator Paul D. Wellstone
Muscular Dystrophy Cooperative Research Center grant U54-NS048843
and NIH contracts N01-AR-5-2274 and NO1-AR-0-2250 to R.T.M.).
The ﬁndings and conclusions in this report are those of the authors and
do not necessarily represent the ofﬁcial position of the Centers for Disease
Control and Prevention or the Agency for Toxic Substances and Disease
Registry.
Disclosures: M.He. serves as a scientiﬁc advisor to Genome Quest,
RainDance, Tessarar, and Oxford Genetic Technologies.Myotonic dystrophy type 1 (DM1) (Steinert disease), the
most common form of adult muscular dystrophy, is a domi-
nantly inherited, multisystem disorder that typically affects
skeletal, smooth, and cardiac muscle, the eyes, the brain, and
endocrine function.1 Although penetrance is approximately
100% by age 50 years, there is variable expressivity, and mild
cases may be misdiagnosed or undiagnosed.2,3
DM1 results from an unstable CTG triplet expansion in
the 30 untranslated region of the DMPK gene (encodesstigative Pathology
.
Myotonic Dystrophy Reference Materialsa serine-threonine kinase) located on chromosome
19q13.3.2,4e6 Individuals not affected by DM1 have 5 to
34 CTG triplet repeats in leukocyte DNA. Patients with
DMPK alleles in leukocyte DNA with 35 to 49 CTG
repeats (premutations) do not have symptoms, but their
children have an increased risk of inheriting larger CTG
repeats and of having symptoms.2
DMPK alleles with CTG repeat expansions >49 lead to
a wide spectrum of symptoms that characterize the DM1
phenotype. Alleles >49 CTG repeats are unstable and may
expand in length during meiosis, causing offspring to inherit
CTG repeats that are longer than those in the parent. These
children often display anticipation deﬁned as an earlier age at
onset of a more severe phenotype than the affected parent.3 In
general, patients with larger CTG repeat expansions in circu-
lating leukocyte DNA tend to have more severe clinical
phenotypes.7e10 However, most patients display somatic tissue
mosaicism in skeletal muscle, heart, and brain, which can
complicate prediction of the phenotype severity.10e13 Patients
with 50 to 100 repeats aremildly affected, usually with cataracts
and/or mild myotonia, which develop later in adulthood. Those
with the classic phenotype (Steinert’s disease) have 101 to 1000
CTG repeats in leukocyte DNA and have classic DM1 symp-
toms, including cataracts, grip myotonia, and distal weakness.
The age at onset for the classical group is approximately late
teens to 30 years. Patients with congenital or childhood
myotonic dystrophy typically present betweenbirth and10years
of age and have more severe manifestations. These patients
typically have>1000 CTG repeats in circulating blood cells.
Molecular genetic testing for DM1 relies primarily on
measurement of the number of CTG repeats in theDMPK gene
isolated from circulating leukocyte DNA. PCR can be used to
measure repeat length in DMPK alleles up to approximately
100 CTG repeats. Southern blot analysis is used to detect
larger expansions. There are currently no US Food and Drug
Administrationeapproved or cleared molecular genetic tests
for DM1. All clinical testing is currently performed using tests
developed in the individual laboratory.
Clinical laboratories use characterized reference materials
for a variety of quality assurance purposes, including test
development, test validation, quality control, and for alter-
native assessment. Proﬁciency testing programs often
distribute characterized genomic DNA reference materials to
their participants. The use of reference materials is also
mandated by regulatory requirements and professional
guidelines for clinical laboratories.14e20 [American College
of Medical Genetics: Standards and Guidelines for Clinical
Genetics Laboratories, http://www.acmg.net/AM/Template.
cfm?Section=Publications1; Washington State Department
of Health, http://www.doh.wa.gov/hsqa/fsl/lqa_home.htm;
College of American Pathologists, http://www.cap.org/
apps/cap.portal?_nfpbZtrue&_pageLabelZaccreditation
(paid subscription required); and New York State Clinical
Laboratory Evaluation Program, http://www.wadsworth.org/
clep, all websites last accessed January 11, 2013.] Reference
materials should be well characterized, homogeneous, andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgclosely resemble an actual clinical specimen.20 Ideally, the
laboratory should use a set of reference materials that contain
the range of mutation types expected for the test that will be
performed. This will allow development and evaluation of
assays to detect a range of variants. Reference materials
containing a range of CTG repeat lengths (from <35 to
several thousand repeats) should be used for development
and evaluation of DM1 genetic tests.
There are no commercial or other sources of characterized
reference materials for molecular genetic testing of DM1.
Laboratories that perform this test typically use character-
ized genomic DNA from cell lines, such as those available
from the National Institute of General Medical Sciences
(NIGMS) repository at the Coriell Institute for Medical
Research (Camden, NJ) or residual patient samples as
reference materials. Laboratories and proﬁciency testing
programs have been unable to obtain many of the necessary
reference materials because cell lines and patient samples
with the complete range of CTG repeat lengths are not
readily available.
To address this need, the Centers for Disease Control and
Prevention’s Genetic Testing Reference Material (GeT-
RM) Coordination Program collaborated with members of
the genetic testing community, the NIGMS repository, and
the NIH-funded National Registry of Myotonic Dystrophy
and Facioscapulohumeral Muscular Dystrophy Patients and
Family Members.21 This report describes the characteriza-
tion of new and preexisting cell lines in three clinical
genetic testing laboratories and the development of a DM1
reference material panel for research and improved clinical
testing.
Materials and Methods
Cell Line Selection
DM1 cell lines with a range of repeat lengths were identiﬁed
in the NIGMS repository at the Coriell Institute for Medical
Research. Myotonic dystrophy repeat lengths that were not
represented in the NIGMS repository were also identiﬁed,
and patients with these repeat lengths were recruited and
asked to donate whole blood for lymphoblast cell line
development. DNA from 13 preexisting cell lines from the
NIGMS repository and 12 newly established lines were
selected for further characterization in one laboratory to
identify candidate reference materials.
Anonymous Blood Collection from Consenting Patients
with Myotonic Dystrophy
New DM1 cell lines were established through collaboration
with the National Registry of Myotonic Dystrophy and
Facioscapulohumeral Muscular Dystrophy Patients and
Family Members at the University of Rochester Medical
Center (Rochester, NY). A protocol and study materials were
prepared and approved by the University of Rochester519
Kalman et alResearch Subjects Review Board. Patients with CTG repeats
in selected size ranges (30 to 49, 50 to 199, and2000) were
recruited by the National Registry through mailed requests.
Patients and their families whowished to donate blood for cell
line creation returned the signed consent form to the
University of Rochester. Consented patients were thenmailed
a blood collection kit containing instructions for the patient,
a letter for the medical care provider who would collect the
blood, blood collection tubes labeled with the deidentiﬁed
research code, and preaddressed and prepaid shipping labels
for sending the blood tubes to the Coriell Cell Repositories.
When the patient visited his or her physician for a regular visit,
bloodwas collected and sent (deidentiﬁed) toCoriell using the
return shipping label and materials provided. Coriell does
not have access to patients’ names or other identifying
information. When the blood specimens were received, each
was assigned a new number and was prepared for cell line
establishment. When the cell line was established, the data
manager requested the deidentiﬁed clinical information from
the patient registry using the corresponding research code.Establishment of New Cell Lines
Cell line creation was performed as previously described.22
Whole blood samples collected from consenting patients or
their families were sent to the Coriell Cell Repositories for
Epstein-Barr virus transformation of B lymphocytes, as
previously described.23,24 All the samples were placed in
culture and were expanded to yield approximately 2  108
total viable cells. The culture medium was antibiotic free to
increase the likelihood that contamination would be readily
detected. The cell suspension was dispensed into forty 1-mL
ampules containing 5  106 viable cells each. Cultures were
cryopreserved in heat-sealed borosilicate glass ampules and
were stored in liquid nitrogen (liquid phase). Successful
cultures were free of bacterial, fungal, and mycoplasma
contamination and were viable after cryopreservation in
liquid nitrogen, as evidenced by doubling of the cell number
within 4 days of recovery.DNA Preparation
DNAwas prepared as previously described.22 Approximately 2
mg of DNA was prepared from cultures of each of the selected
cell lines by the Coriell Cell Repositories using the Gentra
Autopure system (Qiagen Corp., Valencia, CA) per the
manufacturer’s instructions or previously described methods.25Testing Laboratories
Three clinical genetics laboratories that offer testing for
DM1 volunteered to participate in the study. All three
laboratories are located in the United States and are
accredited by the College of American Pathologists.520Reference Material Characterization
Each volunteer laboratory received 20 to 30 mg of DNA
from each of the 10 selected DM1 cell lines. The expected
repeat length was not revealed to the laboratories. The
laboratories genotyped each DNA sample using their
standard DM1 assay. The results were collected by the
study coordinator (L.K.), who examined the data for
discrepancies.
DM1 Assays
Laboratory 1
The number of CTG repeats was determined using PCR
speciﬁc for DMPK alleles with less than approximately 100
repeats.4 PCR was performed using the following primers:
50-CTTCCCAGGCCTGCAGTTTGCCCATC-30 and 50-
GAACGGGGCTCGAAGGGTCCTTGTAGC-30, with the
latter primer being modiﬁed by the addition of 6-FAM
(6-carboxyﬂuorescein) to detect the product by capillary elec-
trophoresis. Approximately 200 to 250 ng of genomic DNA
was ampliﬁed in a total reaction volume of 20 mL. The ﬁnal
concentrations of PCR reagentswere as follows: 1GeneAmp
PCR buffer II, 1.2 mmol/L MgCl2, 200 mmol/L deoxy-
nucleotide mix, 10 ng/mL of each primer, and 1.6 U of
AmpliTaq Gold polymerase (Applied Biosystems/Life Tech-
nologies, Grand Island, NY). Thermocycling conditions in an
Applied Biosystems 9700 or 2720 thermal cycler (Applied
Biosystems/Life Technologies) were as follows: 95C  10
minutes for initial denaturation followed by 25 cycles at
95C 30 seconds, 62C 30 seconds, and 72C 1minute,
with an additional 5 minutes at 72C after the ﬁnal temperature
cycle. One microliter of the ampliﬁed product was mixed with
0.5 mL of GeneScan-500 ROX size standard and 10 mL of
Hi-Di formamide (Applied Biosystems/Life Technologies).
Immediately before loading onto an Applied Biosystems 3130
or 3130 XL genetic analyzer (Applied Biosystems/Life Tech-
nologies), the samples were denatured for 5 minutes at 100C
and then were placed on ice.
Southern blot analysis was performed as previously
described26 using the DNA probe p5B1.4 [a gift from Keith
Johnson (Charing Cross and Westminster Medical School,
London, UK)]. Genomic DNA (5 mg) was separately
digested with 50 U each of EcoRI and BamHI (Promega,
Madison, WI) and was separated by electrophoresis on
a 24-cm-long 1% SeaKem agarose gel (Lonza, Rockland,
ME) containing ethidium bromide (a 0.5-mg/mL ﬁnal
concentration) (Sigma-Aldrich, St. Louis, MO) for approx-
imately 18 hours at 40 V.
Expanded CTG repeat alleles were estimated after auto-
radiography by comparing migration with a 1-kilobase (kb)
DNA ladder (Invitrogen/Life Technologies) on the agarose
gel used for Southern blot analysis. Electrophoretic migra-
tion of the autoradiographic signal from expanded CTG
repeats was measured from the top of the Southern blot
autoradiograph and was visually compared with a image ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
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that contained a ﬂuorescent ruler overlaying the 1-kb DNA
ladder. The ﬂuorescent ruler measures migration from the
top of the agarose gel. The autoradiographic signal mea-
surement from the top of the Southern blot ﬁlter corresponds
to the agarose gel migration distance as measured by the
ruler on the image. When the autoradiographic signal from
expanded repeats was diffuse, a frequent occurrence during
repeat expansion, the midpoint of the signal was used.
CTG repeats were estimated by correlating the measure-
ment after autoradiography with the same distance on the
agarose gel and then comparing this measurement with
electrophoretic migration of the known 1-kb DNA ladder
fragments to obtain an estimate of the size of the expanded
repeat allele.
Laboratory 2
The DM1 gene region containing the expanded CTG repeat
was PCR ampliﬁed with primer pair 50-AACGGGGCTC-
GAAGGGTCCT-30 (forward) and 50-GCCGAAAGAAA-
GAAATGGTCTGT-30 (reverse) in a GeneAmp 9700 PCR
system (Applied Biosystems, Foster City, CA). The PCRs
were performed using 0.5 U of Taq polymerase (Fisher
Scientiﬁc, Waltham, MA) in a total volume of 25 mL con-
taining 50 ng of genomic DNA, 0.8 mmol/L primers, 1
mmol/L MgCl2, and 0.2 mmol/L dNTPs, 0.1 mCi of
32[P]
dCTP (PerkinElmer/NEN Life Sciences, Boston, MA), and
5% dimethyl sulfoxide. The ampliﬁcation was performed
with an initial denaturation at 94C  5 minutes, followed
by 30 cycles of denaturation at 94C  30 seconds,
annealing at 60C  30 seconds, and extension at 72C 
30 seconds. The ﬁnal extension was at 72C for 10 minutes.
The PCR products were separated by electrophoresis on
a 6% denaturing polyacrylamide gel and were visualized by
autoradiography. Allele repeat number was determined by
comparison with standard fragments of known size for
which repeat number had been previously determined by
DNA sequencing analysis.
Southern blot analysis was also performed using 10 mg
of DNA digested with 10 U of SacI restriction enzyme
(New England Biolabs, Ipswich, MA) incubated overnight
at 37C. DNA was precipitated with 3 mol/L sodium
acetate and resuspended in 45 mL of hydration solution
(Qiagen Inc.). All digested DNAs were applied to a 14-cm
1% agarose gel with 1 Tris-acetate-EDTA buffer (pH
8.3). Electrophoresis was performed for 3.5 hours at 94 V.
The Bioline HyperLadder I DNA ladder with 14 bands
ranging from 200 to 10,000 bp (Bioline, Taunton, MA)
was used as the size marker. The DNA was transferred to
a positively charged Millipore S4056 nylon membrane
(Millipore, Billerica, MA) using the Probe Tech transfer
system (Oncor Inc., Gaithersburg, MD) according to the
manufacturer’s directions. The probe pM10M627 was
radiolabeled with a-32[P]dCTP, incubated overnight with
the membrane at 42C, washed with 2 standard saline
citrate (SSC)/0.1% SDS for 30 minutes twice and once atThe Journal of Molecular Diagnostics - jmd.amjpathol.org65C with 0.5 SSC/0.1% SDS for 30 minutes, and,
ﬁnally, autoradiographed for 2 to 5 days using Fuji medical
X-ray ﬁlm (Fisher Scientiﬁc).
In the ﬁrst analysis, bands representing expanded alleles
were estimated by comparison of migration distances of
bands and smears representing expanded alleles with
migration distances of bands in the Bioline HyperLadder I
DNA ladder run on the same gel. In the second analysis,
band size was recalculated from the original autoradiogram.
Distance of migration of bands on the ladder was measured
from the origin and was plotted on semilog paper. Distance
of migration of the midpoint of the band or smear repre-
senting the expanded allele in the samples was measured
and size of the expansion was calculated for the measured
distance using the log scale from the size standards.
Laboratory 3
PCR was performed using approximately 100 ng of genomic
DNA ampliﬁed in a total volume of 15 mL using the primers
50-CTTCCCAGGCCTGCAGTTTGCCCATC-30 (forward, 50
end labeled with 6-Fam) and 50-GAACGGGGCTCGAAG-
GGTCCTTGTAGC-30 (reverse). The ﬁnal concentration of
PCR components was 0.333 mmol/L primers, 1 Q-Solution
(Qiagen Inc.), 2% dimethyl sulfoxide (Fisher, Houston, TX),
dNTP (200 mmol/L dATP, CTP, and dTTP and 50 mmol/L
dGTP; Roche Applied Science, Indianapolis, IN), 167 mmol/L
7-deaza dGTP (Roche Applied Science), 1 ABI buffer
without MgCl2, 2 mmol/L MgCl2, and 1.25U of AmpliTaq
Gold (Applied Biosystems/Life Technologies). The PCR
conditions were as follows: 94C  10 minutes, (95C  1
minute, 69C 2minutes) 10 cycles, (95C 1minute, 65C
 1 minute, 72C  2 minutes) 20 cycles, 4C hold using
a PTC-100 thermal cycler (MJ Research,Waltham,MA). Two
aliquots of PCR products were loaded onto an Applied Bio-
systems 3730XL analyzer (two aliquots of ampliﬁed PCR
productswere used (dilution 1:10 and dilution 1:25) to get clear
results for both normal and abnormal alleles). Diluted PCR
products (2 mL) were mixed with a master cocktail of 18 mL of
Hi-Di formamide and0.1mLofGeneScan-500ROXmolecular
weight marker (Applied Biosystems/Life Technologies).
Samples were denatured at 95C for 3 to 4 minutes and were
placed on ice for 3 minutes. PCR products were separated by
electrophoresis on an ABI 3730XL capillary electrophoresis
instrument and were analyzed using GeneMapper software
version 4.0 (Applied Biosystems/Life Technologies).
For Southern blot analysis, 8 mg of DNAwas digested with
40 U of BglI (New England Biolabs) at 37C overnight, and
an additional 10 U of BglI was spiked into the digest the next
day for 2 hours to ensure complete digestion of genomic
DNA. DNA was separated by electrophoresis on an 11 
14-cm 0.8% agarose LE gel (Roche Applied Science) for
approximately 2 hours at 100V and thenwas increased to 140
V for 2 to 3 hours. Two fragment-sizing ladders were used on
each gel: a 1-kb ladder used to size fragments <10 kb and
a lambda bacteriophage HindIII ladder used to size fragments
10 kb (Promega). DNA was transferred to a charged521
Table 1 Characteristics of Preexisting and Newly Created DM1
Cell Lines
Coriell ID
No. of repeats
As per Coriell or Registry As per laboratory 1
GM06075* 66 55/69 mosaicy
GM03990 50e80 78
GM23265*z 50e60 75
GM23258z 70e80 79
Kalman et alBioBond-Plus nylon membrane (Sigma-Aldrich) using
alkaline transfer with a TurboBlotter apparatus (Whatman-
GE Healthcare, Piscataway, NJ) overnight. The membrane
was baked for 2 hours at 80C before a prehybridization
step at 65C of 4 hours. Hybridization was performed
overnight at 65C. Prehybridization/hybridization buffer
consists of 7% SDS (Roche Applied Science), 1.5 SSPE
(Sigma-Aldrich), 10% w/v polyethylene glycol 8000 (100 g
in 1 L) (Sigma-Aldrich), 250 mg of heparin in 1 L (Sigma-
Aldrich), and 200 ng/mL of salmon sperm DNA (Roche
Applied Science) (salmon sperm is denatured for 10 minutes
at 95C before adding to hybridization buffer).
The DM1 probe was made from a 1090-bp PCR
product generated with primers 9581-F (50-TCCCATGTAA-
GACCCCTCTCTTTCC-30) and 10670-R (50-ATTCCCGG-
CTACAAGGACCCTTCG-30). The probe was labeled with
a-32[P]dCTP using High Prime reaction (Roche Applied
Science). The membrane was washed at 67C for 15 minutes
with 1 low-stringency wash (2 SSC, 0.1% SDS) and at
67C for 30minuteswith 1 high-stringencywash (0.1SSC,
0.5% SDS) and then was placed in a cassette with a phosphoi-
maging screen and was developed using a Storm Imager
system (Amersham Bioscience, Pittsburgh, PA) after 1 to 3
days of exposure.
Repeat size measurements were performed using Image-
Quant TL version 7.0 software (GE Healthcare Biosciences,
Pittsburgh, PA). The migration of each band was measured
to the midpoint of each band or smear. Repeat size was
calculated using the Cubic Spline Curve algorithm provided
with the ImageQuant software.
In the ﬁrst analysis, all bands <10 kb were sized by
comparison with the 1-kb ladder. Larger bands were sized
using the lambda HindIII ladder. In the second analysis, all
bands were sized by comparison with the 1-kb ladder.GM23378*z 80e90 145
GM23299z 90e100 475 mosaic
GM23374z 130e140 475 band not tight
GM23300z 150e160 550 mosaic
GM23256z 160e170 775
GM23391y 170e180 775
GM05164* 340 325
GM03756 <500 450 mosaic
GM03986 <500 550 mosaic
GM03697* <500 370
GM04567* 700 630
GM23358z 800e900 800 band not tight
GM05212 900e1000 875
GM03696* <1000 700
GM04034 <1000 700
GM04648* 1000 950
GM06077 1600 1700
GM05152* 1500 1600
GM03132* <2000 1950
*Cell lines selected for further analysis.
yMosaic: more than one expanded band or smear occurred in the PCR or
Southern blot analysis. Samples with a single repeat value indicate a single
predominant signal.
zNewly created cell lines from DM1 patient blood donations.Results
The goal of this study was to create a comprehensive panel
of publicly available, human cell lineebased genomic DNA
reference materials for myotonic dystrophy genetic testing.
Clinical laboratory directors and representatives of a proﬁ-
ciency testing program were consulted to identify speciﬁc
reference material needs for DM1 molecular genetic testing.
This group suggested that genomic DNA reference materials
should be developed that include a range of CTG repeat
sizes, representing all ﬁve clinical categories: normal (5 to
34 repeats), premutation (35 to 49 repeats), mild DM1 (50 to
100 repeats), classical DM1 (101 to 1000 repeats), and
congenital DM1 (>1000 repeats).2
When this study was initiated, the NIGMS repository at
Coriell had DM1 cell lines with repeat lengths ranging from
300 to 2000 repeats. There were also two cell lines with
approximately 50 to 80 repeats. There were no DM1 cell
lines with CTG repeat lengths at or near the clinical decision
points (35 to 49 CTG repeats). The GeT-RM advisors522recommended that additional cell lines with repeats in the
smaller range (35 to 200 repeats) and repeats in the very
large range (>2000, especially >4000) should be added to
complement the NIGMS collection and to create a compre-
hensive set of DM1 reference materials.
New cell lines with these repeat lengths were created
through collaboration with the National Registry of
Myotonic Dystrophy and Facioscapulohumeral Muscular
Dystrophy Patients and Family Members at the University
of Rochester Medical Center. Using an institutional review
boardeapproved protocol, blood samples from consenting
patients with needed DMPK repeat lengths were collected,
deidentiﬁed, and sent to Coriell to create cell lines. Twenty-
four blood samples were received, and 17 new cell lines
were established. No cell lines with repeat sizes near the
clinical decision points (35 to 49 repeats) were obtained
despite repeated efforts. Several attempts were made to
create cell lines with repeat sizes in the 100 to 200 range.
All six lines made by collection of blood samples from
registry patients with sizes expected to be 90 to 180 triplet
repeats (GM23378, GM23299, GM23374, GM23300,
GM23256, and GM23391) were found to have much larger
repeats when the cell line DNA was analyzed (Table 1).jmd.amjpathol.org - The Journal of Molecular Diagnostics
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existing and 9 newly created) were tested in one volunteer
laboratory (laboratory 1) to conﬁrm the reported CTG repeat
length and to assess their suitability as reference materials.
This laboratory used PCR and Southern blot analysis. The
results are shown in Table 1. Based on this initial assess-
ment of the repeat size in each sample, DNA from 10 cell
lines (NA03696, NA03132, NA05164, NA04648,
NA03697, NA06075, NA05152, NA04567, NA23378, and
NA23265) that best represented the full range of clinically
relevant CTG repeat lengths were selected for further
characterization in the other two volunteer laboratories.
The CTG repeat sizes of both DMPK alleles in the 10
candidate reference materials, as measured by each labora-
tory, are shown in Table 2. The three laboratories tested
each sample using PCR and Southern blot techniques. PCR
is a more accurate method than Southern blot analysis to
determine CTG repeat length; however, this method cannot be
used reliably for alleles with more than approximately 100
repeats. Table 2 indicates CTG repeat length measurements
using PCR for all alleles with<100 repeats (all normal alleles,
and expanded alleles in samples NA06075 and NA23265).
Repeat lengths for alleles with >100 repeats in Table 2 were
calculated using Southern blot analysis. Consensus values
were calculated by averaging measurements from each labo-
ratory and calculating the population SD, a measure of how
widely values are dispersed from the mean, using Excel soft-
ware version 14.0.6129.5000 (Microsoft Corp., Redmond,
WA). There were no discrepancies among laboratories in the
measurements by PCR of the smaller, normal DMPK allele in
each sample. The DNA size measurements derived from PCR
performed by the three laboratories of the mosaic expanded
alleles in sample NA06075 were nearly identical. Similarly,
laboratories 1 and 3 measured the expanded allele in sample
NA23265 using PCR and obtained almost identical repeat
lengths (75 and 74, respectively). Laboratory 2 obtained
a value of 100 repeats in this sample using Southern blotTable 2 CTG Repeat Length in DNA from 10 DM1 Cell Lines
Coriell no.
Allele 1, 2
Laboratory 1 Laboratory 2
NA06075* 12, 55, 69 (mosaic) 12, 56, 71 (mosa
NA23265y 12, 75 12, NDz
NA23378x 22, 145 22, 135
NA05164 21, 325 21, 450
NA03697{ 12, 370 12, 450
NA04567 21, 630 21, 600
NA03696 12, 700 12, 680
NA04648 5, 950 5, 1070
NA05152 5, 1600 5, 1600
NA03132 5, 1950 5, 1900
*Laboratory 3 measured an expanded allele in this sample with 88 CTG repeat
yLaboratory 2 detected an expanded allele with 100 repeats using Southern blo
repeats using Southern blot hybridization.
zND, not determined. Laboratory 2 did not measure the expanded allele in thi
xLaboratory 3 detected two expanded alleles (74 and 125 repeats) in this sam
{Laboratory 2 detected a minor band measuring 530 repeats using Southern b
The Journal of Molecular Diagnostics - jmd.amjpathol.organalysis but did not use PCR because the PCR assay failed to
produce a product for this sample.
The three laboratories varied slightly in the measurement
of the larger expanded alleles, which were analyzed using
Southern blot hybridization, a technique that is inherently
less accurate than PCR. The calculated population SD was
<10% for all the expanded alleles, except the 2078 repeat
alleles in NA03132 (10.4%) and the 377 repeat alleles in
NA05164 (14.1%).
Discussion
We identiﬁed a set of characterized, cell lineebased
genomic DNA reference materials for DM1 genetic testing
(Table 2). These materials were characterized in three
clinical genetic testing laboratories using PCR and Southern
blot analysis. The DMPK alleles in the samples include four
of the ﬁve clinical categories: normal (5 to 34 repeats)
(10 alleles), mild DM1 (50 to 100 repeats) (three alleles),
classical DM1 (101 to 1000 repeats) (ﬁve alleles), and
congenital DM1 (>1000 repeats) (three alleles).2 We did
not identify any preexisting cell lines in the Coriell collec-
tion with repeats in the premutation range (35 to 49 repeats),
and neither did we create any lines in this size range from
patients in the National Registry. The smallest expanded
repeat we identiﬁed was 55 repeats (NA06075), which is
close to the clinical decision points (35 to 49 CTG repeats).
Five new cell lines created from patients with DM1 were
expected to have expanded alleles with 90 to 180 CTG
repeats; however, each was found to have a much larger
expanded allele after cell line creation (Table 1). These
patients had reported their CTG repeat size to the Registry
based on genetic tests performed 5 to 15 years before the
creation of their cell lines for this project, and the CTG
repeat size was not measured from the blood samples used
to create the cell lines. Previously used methods may have
been less accurate, or data transcription errors may haveLaboratory 3 Consensus size
ic) 12, 55, 69 (mosaic) 12, 56, 70 ( 0.9)
12, 74 12, 75
22, 135 22, 138 ( 5)
21, 357 21, 377 ( 53)
12, 417 12, 412 ( 33)
21, 680 21, 637 ( 33)
12, 710 12, 697 ( 13)
5, 1005 5, 1008 ( 49)
5, 1664 5, 1621 ( 30)
5, 2384 5, 2078 ( 217)
s using Southern blot analysis.
t analysis in this sample. Laboratory 3 measured an expanded allele with 72
s sample using PCR.
ple using PCR.
lot analysis in this sample.
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Kalman et aloccurred. CTG repeats in patients with DM1 are known to
be unstable, and repeat size has been shown to increase over
time.28 It is possible that the DMPK alleles in these patients’
peripheral blood cells have expanded signiﬁcantly since the
patients were initially tested or that the samples themselves
are unstable as a result of Epstein-Barr virus transformation
or clonal expansion during cell culture.
The potential instability of the CTG expansion in these
cell lines should not affect the usefulness of these samples
as reference materials when isolated genomic DNA is used
for testing because several milligrams of genomic DNA
were isolated from the cell line. The repeat length in the
isolated DNA sample should remain stable over time. In
addition, the procedures used by the Coriell Cell Reposi-
tories to propagate cell lines are designed to limit the
number of cell divisions after establishment of the line,
which reduces the possibility of accumulating additional
mutations. The standard protocol for banking cell cultures in
the Coriell Cell Repositories is to create an initial frozen cell
culture stock and to reserve a portion of it for replenishment
of frozen cell culture stock and expansion for DNA isolation
for distribution. This procedure ensures that distribution
stocks are only six or seven population doublings beyond
the earliest available stocks and minimizes the opportunity
for accumulation of mutations. It is recommended, however,
that all users of any reference material should conﬁrm the
expected genotype in their own laboratory.20 We also
recommend that owing to the potential instability of the
CTG expansion, clinical laboratories use the DNA charac-
terized during this study as reference materials rather than
the associated cell lines because the latter have not been
evaluated for stability or suitability as reference materials.
The College of American Pathologists proﬁciency testing
survey for DM1 evaluates participants by their ability to
correctly interpret their results (consistent or not consistent
with DM1) but does not currently grade the reported repeat
length measurements [http://www.cap.org/apps/cap.portal?
_nfpbZtrue&_pageLabelZaccreditation (paid subscrip-
tion required), last accessed January 11, 2013]. The partic-
ipants in this programcan almost alwaysmeasure the size of the
smaller, normal repeat-length alleles correctly, but there iswide
variation in the reported size of the larger, expanded alleles.29
This variation typically does not affect the participants’
ability to identify samples with expanded alleles or to correctly
interpret the clinical diagnostic results because the repeat
lengths of the diagnostic decision points (35 to 49 repeats) are
accurately assigned by PCR ﬁndings. Similarly, in this study,
the three laboratories were able to consistently measure the
smaller alleles; however, they initially reported widely
discrepant results for the expanded alleles (data not shown). On
reanalysis of the Southern blot data using a common standard
of measurement (migration to the midpoint of each band or
smear), the repeat size of the expanded alleles reported by each
laboratory achieved more concordance. This observation
suggests that adoption of a common method for measurement
and calculation of expanded allele length will help standardize524reporting of the CTG repeat sizes in blood samples of patients
with DM1 and may allow proﬁciency testing programs to
evaluate participants based on their reported expanded allele
repeat lengths. Use of these characterized genomic DNA
samples during assay development and validation can also help
laboratories evaluate the capacity of their DMPK assays to
obtain accurate results.
This study highlights the important role that patient
advocacy groups and cell registries, such as the NIH-funded
National Registry at the University of Rochester, can have
in the improvement of laboratory services and for basic
scientiﬁc research. Resources, such as publicly available
DNA, cell lines, and tissue samples, for rare disorders are
limited and may be difﬁcult to obtain. Patient groups are
becoming aware of their role in the development of new
tests and treatments for their rare disorders and are often
active partners with the research and clinical communities.
The willingness of patients with DM1 and their families to
share their resources with the genetics community through
the Coriell Cell Repositories will beneﬁt not only the quality
but also the availability of genetic testing for DM1.
The genomic DNA reference materials characterized in
this study will be useful for quality control, proﬁciency
testing, test development and validation, and research. DNA
samples puriﬁed from these cell lines, and other DNA
samples characterized by the GeT-RM, are publicly avail-
able from the NIGMS repository at the Coriell Cell
Repositories. More information about the GeT-RM program
and available reference materials are available from the
GeT-RM Coordination Program (http://wwwn.cdc.gov/dls/
genetics/RMMaterials, last accessed January 11, 2013).
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